A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects With Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC)

Progressive Familial Intrahepatic Cholestasis (PFIC) Clinical Trial

— MARCH-PFIC  

Official title:

MRX-502: Randomized Double-blind Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Maralixibat in the Treatment of Subjects With Progressive Familial Intrahepatic Cholestasis (PFIC) - MARCH-PFIC

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03905330
• Other study ID #: MRX-502
• Secondary ID: 2019-001211-22
• Status: Completed
• Phase: Phase 3
• Start date: July 9, 2019
• Est. completion date: September 1, 2022

Study information

• Verified date: December 2023
• Source: Mirum Pharmaceuticals, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine whether the investigational treatment (maralixibat) is safe and effective in pediatric participants with Progressive Familial Intrahepatic Cholestasis (PFIC).

Description:

This study was conducted at multiple sites in North America, Europe, Asia and South America.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 93
• Est. completion date: September 1, 2022
• Est. primary completion date: September 1, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 1 Year to 17 Years

Eligibility

Inclusion Criteria:

1. Informed consent and assent (as applicable) per Institutional Review Board/Ethics Committee (IRB/EC)

2. Male or female subjects with a body weight =5 kg, who are =12 months and <18 years of age at time of baseline

3. Cholestasis as manifested by total sBA =3× ULN (applies to primary cohort only)

4. An average AM ItchRO(Obs) score =1.5 during 4 consecutive weeks of the screening period, leading to the baseline visit (Visit 1)

5. Completion of at least 21 valid* morning ItchRO(Obs) entries during 4 consecutive weeks of the screening period, leading to the baseline visit (Visit 1) (*valid = completed and not answered as "I don't know"; maximum allowed invalid reports = 7, no more than 2 invalid reports during the last 7 days before randomization)

6. Diagnosis of PFIC based on the following:

• Chronic cholestasis as manifested by persistent (>6 months) pruritus in addition to biochemical abnormalities and/or pathological evidence of progressive liver disease and

• Primary Cohort: Subjects with genetic testing results consistent with biallelic disease-causing variation in ABCB11 (PFIC2), based on standard of care genotyping

• Supplemental Cohort: i. Subjects with genetic testing results consistent with biallelic disease-causing variation in ATP8B1 (PFIC1), ABCB4 (PFIC3), or TJP2 (PFIC4), based on standard of care genotyping. ii. Subjects with PFIC phenotype without a known mutation or with another known mutation not described above or with intermittent cholestasis as manifested by fluctuating sBA levels. iii. Subjects with PFIC after internal or external biliary diversion surgery or for whom internal or external biliary diversion surgery was reversed.

7. Male and females of non-childbearing potential. Males and non-pregnant, non-lactating females of childbearing potential who are sexually active must agree to use acceptable methods of contraception during the study and 30 days following the last dose of the study medication. Females of childbearing potential must have a negative pregnancy test

8. Access to email or phone for scheduled remote visits

9. Ability to read and understand the questionnaires (both caregivers and subjects above the age of assent)

10. Access to consistent caregiver(s) during the study

11. Subject and caregiver willingness to comply with all study visits and requirements.

Exclusion Criteria:

1. Predicted complete absence of bile salt excretion pump (BSEP) function based on the type of ABCB11 mutation (PFIC2), as determined by a standard of care genotyping (applies to primary cohort only). Subjects can enter the study in the Supplemental Cohort (under inclusion criteria 6.ii or 6.iii).

2. Recurrent intrahepatic cholestasis, indicated by a history of sBA levels <3x ULN or intermittent pruritus (applies to primary cohort only)

3. Current or recent history (<1 year) of atopic dermatitis or other non-cholestatic diseases associated with pruritus.

4. History of surgical disruption of the enterohepatic circulation (applies to primary cohort only)

5. Chronic diarrhea requiring intravenous fluid or nutritional intervention for the diarrhea and/or its sequelae at screening or during the 6 months prior to screening

6. Previous or need for imminent liver transplant

7. Decompensated cirrhosis (international normalized ratio [INR] >1.5, albumin <30 g/L, history or presence of clinically significant ascites, variceal hemorrhage, and/or encephalopathy)

8. ALT or total serum bilirubin (TSB) >15× ULN at screening

9. Presence of other liver disease

10. Presence of any other disease or condition known to interfere with the absorption, distribution, metabolism or excretion of drugs, including bile salt metabolism in the intestine (e.g., inflammatory bowel disease), per Investigator discretion

11. Possibly malignant liver mass on imaging, including screening ultrasound

12. Known diagnosis of human immunodeficiency virus (HIV) infection

13. Any prior cancer diagnosis (except for in situ carcinoma) within 5 years of the screening visit (Visit 0)

14. Any known history of alcohol or substance abuse

15. Administration of bile acids or lipid binding resins, or phenylbutyrates during the screening period

16. Criterion has been deleted as of Amendment 3

17. Administration of any investigational drug, biologic, or medical device during the screening period

18. Previous use of an ileal bile acid transporter inhibitor (IBATi)

19. History of non-adherence to medical regimens, unreliability, medical condition, mental instability or cognitive impairment that, in the opinion of the Investigator or Sponsor medical monitor, could compromise the validity of informed consent, compromise the safety of the subject, or lead to nonadherence with the study protocol or inability to conduct the study procedures

20. Known hypersensitivity to maralixibat or any of its excipients.

Related Conditions & MeSH terms

• Cholestasis
• Cholestasis, Intrahepatic
• Progressive Familial Intrahepatic Cholestasis (PFIC)

Intervention

Drug:
• Maralixibat
Maralixibat oral solution (up to 600 mcg/kg) orally twice daily for 26 weeks.

Other:
• Placebo
Placebo matching to maralixibat orally twice daily for 26 weeks.

Locations

Country	Name	City	State
Argentina	Hospital Italiano de Buenos Aires	Buenos Aires
Austria	Medizinische Universität Wien, Universitätsklinik für Kinder- und Jugendheilkunde	Wien
Belgium	Universite Catholique de Louvain (UCLouvain) - Cliniques Universitaires Saint-Luc	Bruxelles
Brazil	Sociedade Beneficente de Senhoras Hospital Sírio-Libanês	São Paulo
Canada	University of Alberta - Women and Children's Health Research Institute	Edmonton
Colombia	Fundacion Cardioinfantil - Departamento de Investigaciones	Bogotá
France	Hospices Civils de Lyon - Hopital Femme Mere Enfant Service de Gastroenterologie, Hepatologie et Nutrition	Lyon
France	CHU de Marseille, Hôpital de la Timone	Marseille
France	CHU de Toulouse - Hôpital des Enfants	Toulouse
Germany	Medizinische Hochschule Hannover	Hanover
Hungary	Semmelweis Egyetem - Altalanos Orvostudomanyi Kar (SE AOK)	Budapest
Italy	Hospital Papa Giovanni XXIII / Unità di Pediatria	Bergamo
Italy	Ospedale Pediatrico Bambino Gesu	Roma
Lebanon	Hotel Dieu de France	Beirut
Mexico	Consultario de Joshue David Covarrubias Esquer	Zapopan
Poland	Instytut Pomnik Centrum Zdrowia Dziecka	Warsaw
Singapore	KK Women's and Children's Hospital	Singapore
Turkey	Koc University Hospital	Istanbul
United Kingdom	Birmingham Children's Hospital	Birmingham
United Kingdom	King's College Hospital NHS	London
United States	Medical University of South Carolina	Charleston	South Carolina
United States	Cincinnati Children's Hospital	Cincinnati	Ohio
United States	Cleveland Clinic - Pediatric Institute	Cleveland	Ohio
United States	University of Texas - UT Southwestern Medical Center	Dallas	Texas
United States	Children's Hospital Los Angeles CHLA	Los Angeles	California
United States	The Children's Hospital at Montefiore Yeshiva University - Montefiore Medical Center	New York	New York
United States	Advent Health	Orlando	Florida
United States	UPMC Children's Hospital of Pittsburgh	Pittsburgh	Pennsylvania
United States	University of Texas, Health Science Center San Antonio	San Antonio	Texas
United States	Seattle Children's Hospital	Seattle	Washington
United States	Medstar Georgetown University Hospital	Washington	District of Columbia

Sponsors (1)

Lead Sponsor	Collaborator
Mirum Pharmaceuticals, Inc.

Countries where clinical trial is conducted

United States,  Argentina,  Austria,  Belgium,  Brazil,  Canada,  Colombia,  France,  Germany,  Hungary,  Italy,  Lebanon,  Mexico,  Poland,  Singapore,  Turkey,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mean Change in the Average Morning ItchRO(Obs) Severity Score in the Primary Cohort	The primary efficacy endpoint is the mean change in the average morning ItchRO(Obs) severity score between baseline and Weeks 15-26, using 4-week average morning ItchRO(Obs) severity scores (Mixed Model Repeated Measures). The baseline average morning ItchRO(Obs) severity score is defined as the 4-week average morning ItchRO(Obs) severity score prior to the first dose of the study medication.; ItchRo(Obs) Severity Score = Itch Reported Outcome Observer assessment severity score; scale between 0 (not itchy at all) and 4 (extremely itchy); the lower the score the better.	MMRM model was used with inputs of the average changes from baseline (BL) to Weeks 1-6, 7-10, 11-14, 15-18, 19-22, 23-26, and other covariates. The average change from BL over Weeks 15-26 is calculated in the model and presented as a single number.
Secondary	Mean Change in Total sBA Level in the Primary Cohort.	Mean change in total sBA level between baseline and average of Weeks 18, 22 and 26.	Baseline and average of Weeks 18, 22 and 26
Secondary	Mean Change in the Average Morning ItchRO(Obs) Severity Score in Participants With PFIC (PFIC1, Nt-PFIC2, PFIC3, PFIC4 and PFIC6)	Mean change in the average morning ItchRO(Obs) severity score between baseline and Week 15 through Week 26 in participants with PFIC (PFIC1, PFIC2, PFIC3, PFIC4 and PFIC6).; ItchRo(Obs) Severity Score = Itch Reported Outcome Observer assessment severity score; scale between 0 (not itchy at all) and 4 (extremely itchy); the lower the score the better.	Between Baseline and Week 15 through Week 26
Secondary	Mean Change in Total sBA Level in Participants With PFIC (PFIC1, PFIC2, PFIC3, PFIC4 and PFIC6)	Mean change in total sBA level between baseline and average of Weeks 18, 22, and 26 in participants with PFIC (PFIC1, PFIC2, PFIC3, PFIC4 and PFIC6)	Between Baseline and average of Weeks 18, 22 and 26
Secondary	Proportion of ItchRO(Obs) Responders in the Primary Cohort	Proportion of ItchRO(Obs) responders from Week 15 to Week 26 in participants with PFIC2 using the average value from the three 4-week periods (Weeks 15-18, 19-22 and 23-26). The number in the Subject Analysis Set refers to the number of responders.; ItchRO responders are defined as a subject having a 4-week average morning ItchRO(Obs) severity change from baseline of =-1.0 or an average severity score of =1.0.	Week 15 to Week 26 using the average value from the three 4-week periods (Weeks 15-18, 19-22 and 23-26)
Secondary	Proportion of sBA Responders in the Primary Cohort	Proportion of sBA responders from Week 18 to Week 26 in participants with PFIC2, using the average value from Weeks 18, 22 and 26 values. The number in the Subject Analysis Set refers to the number of responders.; sBA responders are defined as a subject having an average sBA level of <102 umol/L (applies only if baseline sBA level was =102 umol/L), OR a =-75% average percent change from baseline.	Average value from Weeks 18, 22 and 26
Secondary	Proportion of ItchRO(Obs) Responders PFIC (PFIC1, PFIC2, PFIC3, PFIC4 and PFIC6)	Proportion of ItchRO(Obs) responders from Week 15 to Week 26 in participants with PFIC (PFIC1, PFIC2, PFIC3, PFIC4 and PFIC6). The number in the Subject Analysis Set refers to the number of responders.; ItchRO responders are defined as a subject having a 4-week average morning ItchRO(Obs) severity change from baseline of =-1.0 OR an average severity score of =1.0.	From Week 15 to Week 26
Secondary	Proportion of sBA Responders PFIC (PFIC1, PFIC2, PFIC3, PFIC4 and PFIC6)	Proportion of sBA responders from Week 18 to Week 26 in participants with PFIC (PFIC1, PFIC2, PFIC3, PFIC4 and PFIC6). The number in the Subject Analysis Set refers to the number of responders.; sBA responders are defined as a subject having an average sBA level of <102 umol/L (applies only if baseline sBA level was =102 umol/L), or a =-75% average percent change from baseline.	Week 18 to Week 26

External Links

•   Genetics Home Reference - PFIC
•   Mirum Pharmaceuticals homepage
•   US FDA Resources